Targeted pharmacological reversal of electrical remodeling after cardioversion

Trial Profile

Targeted pharmacological reversal of electrical remodeling after cardioversion

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Flecainide (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms Flec-SL
  • Most Recent Events

    • 02 Jul 2012 Additional lead trial centres and investigator, actual patient number 760 added as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Results published in the Lancet.
    • 02 May 2011 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top